Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092711 | 0.83 | DAO (0.40) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL6657810 | 0.81 | DAO (0.52) | DAOMAOBKDM1AHRH3DRD2 | |
| SCHEMBL26501053 | 0.81 | DAO (0.52) | DAOMAOBKDM1AHRH3DRD2 | |
| SCHEMBL12448058 | 0.81 | DAO (0.39) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL21386592 | 0.79 | ALDH1A1 (0.40) | HRH3DRD3NPC1 | |
| SCHEMBL13509554 | 0.79 | MAOB (0.41) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL23868234 | 0.78 | MAOB (0.40) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL20331224 | 0.78 | MAOB (0.40) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL18705117 | 0.78 | DAO (0.37) | DAOMAOBKDM1AMAOAHRH3 | |
| SCHEMBL19557934 | 0.78 | DAO (0.37) | DAOMAOBKDM1AMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR3, TLR9 | DAO 1290/4885MAOB 3487/4885KDM1A 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.